当前位置: X-MOL 学术Blood › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: Results from a phase 2a study
Blood ( IF 20.3 ) Pub Date : 2018-01-11 , DOI: 10.1182/blood-2017-06-790121
Ali T Taher 1 , Zeynep Karakas 2 , Elena Cassinerio 3 , Noppadol Siritanaratkul 4 , Antonis Kattamis 5 , Aurelio Maggio 6 , Stefano Rivella 7 , Norbert Hollaender 8 , Bruyère Mahuzier 9 , Brian Gadbaw 10 , Yesim Aydinok 11
Affiliation  

To the editor: Ineffective erythropoiesis is a key pathological feature in thalassemia and is the major perpetrator of profound anemia and hypoxia seen in these patients.[1][1][⇓][2]-[3][3] The inadequate tissue oxygenation in thalassemia sets up several compensatory mechanisms, including an

中文翻译:

鲁索替尼在定期输血的地中海贫血患者中的有效性和安全性:来自 2a 期研究的结果

致编者:无效的红细胞生成是地贫的一个关键病理特征,是这些患者出现严重贫血和缺氧的主要原因。[1][1][⇓][2]-[3][3] 组织不足地贫中的氧合作用建立了几种代偿机制,包括
更新日期:2018-01-11
down
wechat
bug